arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6

Tuesday, September 22, 2015 1 min read

Key Takeaway: arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6

Full Press Release Details

arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6.